Promethera Biosciences
Promethera Biosciences is a privately held Belgium-based biopharmaceutical company founded in 2009 that develops cell therapy products to treat liver diseases, having raised approximately $149 million across multiple funding rounds through 2019.
- Company typePrivate
- Founded2009
- HeadquartersMont-saint-guibert, Belgium
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Promethera Biosciences does
Promethera Biosciences is a Belgium-based, privately held biopharmaceutical company founded in 2009 and headquartered in Mont-Saint-Guibert that develops cell therapy products for the treatment of liver diseases. The company operates in the advanced therapy medicinal product (ATMP) domain, building biological assets aimed at patients with liver disorders, and has expanded its capabilities through inorganic moves, including the April 2018 acquisition of Baliopharm.
The company has funded its development through a sustained series of equity rounds totaling approximately $149 million between 2010 and 2019, drawing a mix of specialized life-sciences investors (EQT Life Sciences, Vesalius Biocapital Partners, Fund+, S.R.I.W.), Belgian public investors (SFPI-FPIM, Limburgse Reconversie Maatschappij), strategic corporate investors (Boehringer Ingelheim and its Venture Fund, Shire), and Asian institutional and corporate backers (Mitsui Global Investment, Mitsubishi UFJ Capital, Shibuya Kogyo, Shinsei Corporate Investment, Sansei Capital Investment, Sony Innovation Fund, Pegasus Tech Ventures). The leadership team is led by CEO and President John Tchelingerian, with Claude Dedry as Chief Operating Officer, William Macias as Chief Medical Officer ad interim, and Bertrand Lellouche as Group CFO, and the organization employs between 101 and 250 people.
No commercial product, pricing structure, revenue model, partnership economics, customer base, or product pipeline detail is disclosed in the available input data. The company remains private and pre-commercial in the observable record, with strategic activity concentrated in capital raising and selective M&A. The website scrape associated with the firmographic record contained unrelated Vietnamese-language sports news content rather than biotech-specific company information, limiting the granularity of first-party operational data.
Promethera Biosciences firmographics
Firmographics- Name
- Promethera Biosciences
- Website
- https://promethera.com
- Company type
- Private
- Founded year
- 2009
- Headcount range
- 101–250 employees
- Short description
- Promethera Biosciences is a privately held Belgium-based biopharmaceutical company founded in 2009 that develops cell therapy products to treat liver diseases, having raised approximately $149 million across multiple funding rounds through 2019.
- Ownership category
- akta.pro rank
Promethera Biosciences industry classification
Industry- Product category
- Cell Therapy Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- Hepatology & Liver Disease (HLAKAEAB), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
Keywords
Where Promethera Biosciences is headquartered
LocationHeadquarters
- HQ city
- Mont-saint-guibert
- HQ country
- Belgium
- HQ region
- Europe
Markets served
Promethera Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Promethera Biosciences product offering
Product offeringCore offering
Promethera Biosciences develops and manufactures cell therapy products aimed at treating liver diseases. The company operates as a biopharmaceutical firm focused on biological therapeutics for hepatic conditions, including advanced therapies derived from cell-based platforms. Its work centers on translating cell therapy science into treatments for patients with serious liver disorders.
Product overview
Promethera.com is a unified sports news portal that aggregates and publishes Vietnamese-language content across three sports verticals: football (bóng đá), baseball (bóng chày), and table tennis (bóng bàn). The platform publishes educational articles about sports rules, techniques, equipment, player profiles, stadium histories, and transfer news.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell therapy products for liver diseases
Companies that use Promethera Biosciences
Customer profileIdeal customer profiles1 record
Promethera Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Promethera Biosciences partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights4 records
Promethera Biosciences competitors and assessment
Company assessmentDirect peers
- Promethera Biosciences (HepaStem asset): Note: Promethera Biosciences is the subject company; this row is intentionally not used as a peer.
- Lygenesis: Clinical-stage cell therapy company developing allogeneic liver cell therapies delivered via lymph node injection to regenerate liver function. Directly comparable to Promethera's HepaStem approach in liver disease indications.
- Allogene Therapeutics: Clinical-stage allogeneic CAR T cell therapy developer. Comparable as an allogeneic cell therapy platform company with similar manufacturing, regulatory, and development challenges, though focused on oncology rather than liver disease.
- Atara Biotherapeutics: Allogeneic T-cell therapy developer with off-the-shelf platform. Comparable business model as an allogeneic cell therapy company with similar manufacturing approach and clinical development timelines.
Emerging players
- MiNA Therapeutics: UK-based clinical-stage biotech developing RNA-based therapeutics for liver disease and cancer. Comparable as a liver-focused biotech with platform technology targeting similar indications, though using RNA activation rather than cell therapy.
- Humacyl Pharma: Earlier-stage cell therapy company developing regenerative therapies. Comparable as a smaller cell therapy peer in the regenerative medicine space.
Broad incumbents
- Terumo BCT: Established cell and blood processing technology provider. Comparable as an infrastructure player in the cell therapy ecosystem, though serving the broader cell therapy industry rather than competing in liver disease specifically.
- Vertex Pharmaceuticals: Major biopharmaceutical company with significant cell therapy programs (via ViaCyte acquisition for diabetes) and broader hepatology franchise through CF treatments. Comparable as a well-capitalized player moving into cell therapy.
- Takeda Pharmaceutical (Shire): Global pharmaceutical company and Promethera investor (via Shire acquisition). Has significant hepatology and rare disease franchises and could serve as an exit/partner for Promethera's liver programs.
- Roche: Major pharmaceutical company with significant hepatology franchise (e.g., Pegasys, hepatitis treatments). Relevant as a potential commercial partner or acquirer for liver disease therapies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Promethera Biosciences social profiles
Digital presencePromethera Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Promethera Biosciences leadership team
Management profileNumber of profiles
Profiles4 records
Promethera Biosciences funding detail
Funding detailFunding overview
Funding rounds7 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Promethera Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Promethera Biosciences
What does Promethera Biosciences do?
Promethera Biosciences develops and manufactures cell therapy products aimed at treating liver diseases. The company operates as a biopharmaceutical firm focused on biological therapeutics for hepatic conditions, including advanced therapies derived from cell-based platforms. Its work centers on translating cell therapy science into treatments for patients with serious liver disorders.
When was Promethera Biosciences founded?
Promethera Biosciences was founded in 2009. It employs 101 to 250 people.
Where is Promethera Biosciences based?
Promethera Biosciences is headquartered in Mont-saint-guibert, Belgium, in the Europe region.
Who are Promethera Biosciences's main competitors?
Direct peers on record are Promethera Biosciences (HepaStem asset), Lygenesis, Allogene Therapeutics and Atara Biotherapeutics. Emerging players are MiNA Therapeutics and Humacyl Pharma. Broad incumbents are Terumo BCT, Vertex Pharmaceuticals, Takeda Pharmaceutical (Shire) and Roche.
Does Promethera Biosciences have an API?
No public API is recorded for Promethera Biosciences.
What industry is Promethera Biosciences in?
Promethera Biosciences's product category is Cell Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAKAEAB, Hepatology & Liver Disease. Its NAICS code is 325414 and its SIC code is 2836.